Protalix BioTherapeutics, Inc. (DE) (PLX): Price and Financial Metrics


Protalix BioTherapeutics, Inc. (DE) (PLX): $0.99

-0.01 (-1.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PLX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 476

in industry

PLX POWR Grades


  • PLX scores best on the Value dimension, with a Value rank ahead of 79.7% of US stocks.
  • The strongest trend for PLX is in Stability, which has been heading down over the past 52 weeks.
  • PLX ranks lowest in Stability; there it ranks in the 5th percentile.

PLX Stock Summary

  • Protalix BioTherapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 99.98% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -42.74 for Protalix BioTherapeutics Inc; that's greater than it is for merely 0.59% of US stocks.
  • The volatility of Protalix BioTherapeutics Inc's share price is greater than that of 99.23% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to PLX, based on their financial statements, market capitalization, and price volatility, are WMG, CAH, IEA, SEAS, and STCN.
  • PLX's SEC filings can be seen here. And to visit Protalix BioTherapeutics Inc's official web site, go to www.protalix.com.

PLX Valuation Summary

  • In comparison to the median Healthcare stock, PLX's price/sales ratio is 85.9% lower, now standing at 1.6.
  • Over the past 243 months, PLX's price/sales ratio has gone NA NA.
  • Over the past 243 months, PLX's EV/EBIT ratio has gone down 7.8.

Below are key valuation metrics over time for PLX.

Stock Date P/S P/B P/E EV/EBIT
PLX 2021-08-31 1.6 19.4 -3.6 -8.2
PLX 2021-08-30 1.5 18.6 -3.4 -7.9
PLX 2021-08-27 1.5 19.0 -3.5 -8.0
PLX 2021-08-26 1.5 18.1 -3.4 -7.8
PLX 2021-08-25 1.4 17.5 -3.2 -7.6
PLX 2021-08-24 1.3 16.4 -3.0 -7.3

PLX Growth Metrics

  • Its 2 year price growth rate is now at -14%.
  • Its 2 year cash and equivalents growth rate is now at -65.72%.
  • The 4 year revenue growth rate now stands at 122137.04%.
PLX's revenue has moved up $44,932,000 over the prior 70 months.

The table below shows PLX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 49.296 -12.748 -20.518
2021-06-30 48.032 -14.472 -20.756
2021-03-31 52.572 -28.823 -13.665
2020-12-31 62.898 -26.106 -6.523
2020-09-30 61.162 -22.243 -6.629
2020-06-30 64.62 -21.864 -5.752

PLX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PLX has a Quality Grade of C, ranking ahead of 73.31% of graded US stocks.
  • PLX's asset turnover comes in at 0.547 -- ranking 71st of 681 Pharmaceutical Products stocks.
  • MNKD, XTNT, and NBIX are the stocks whose asset turnover ratios are most correlated with PLX.

The table below shows PLX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.547 0.685 -0.240
2021-03-31 0.668 0.768 -0.088
2020-12-31 0.853 0.827 0.039
2020-09-30 0.898 0.819 0.028
2020-06-30 1.019 0.823 0.046
2020-03-31 1.111 0.814 -0.008

PLX Stock Price Chart Interactive Chart >

Price chart for PLX

PLX Price/Volume Stats

Current price $0.99 52-week high $7.02
Prev. close $1.00 52-week low $0.86
Day low $0.95 Volume 196,000
Day high $1.02 Avg. volume 1,313,732
50-day MA $1.19 Dividend yield N/A
200-day MA $2.60 Market Cap 45.10M

Protalix BioTherapeutics, Inc. (DE) (PLX) Company Bio


Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company was founded in 1993 and is based in Carmiel, Israel.


PLX Latest News Stream


Event/Time News Detail
Loading, please wait...

PLX Latest Social Stream


Loading social stream, please wait...

View Full PLX Social Stream

Latest PLX News From Around the Web

Below are the latest news stories about Protalix BioTherapeutics Inc that investors may wish to consider to help them evaluate PLX as an investment opportunity.

PLX: Third Quarter Update

By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced its 3Q:21 financial and operational results in a November 15, 2021 press release and filing of Form 10-Q . Promulgation of the reports was followed by a pre-market conference call which discussed recent achievements. Operational

Yahoo | November 15, 2021

Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the third quarter ended September 30, 2021 and provided a financial and business update on recent corporate, clinical and regulatory developments.

Yahoo | November 15, 2021

Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021

Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel , Nov. 8, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins

Protalix Biotherapeutics | November 8, 2021

Protalix BioTherapeutics Inc (PLX): Price Now Near $1.21; Daily Chart Shows Downtrend on 100 Day Basis

The moving averages on the daily timeframe suggest a bearishness in price, as the 20, 50, 100 and 200 are all in a bearish alignment -- meaning the shorter duration moving averages are below the longer duration averages, implying a stable downward trend. The post Protalix BioTherapeutics Inc (PLX): Price Now Near $1.21; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .

ETF Daily News | October 19, 2021

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced the final dosing of the last patient in the phase III BALANCE cl

Yahoo | October 15, 2021

Read More 'PLX' Stories Here

PLX Price Returns

1-mo -11.61%
3-mo -38.13%
6-mo N/A
1-year -72.65%
3-year -76.43%
5-year -79.80%
YTD -72.73%
2020 10.67%
2019 5.47%
2018 -52.95%
2017 50.23%
2016 -56.86%

Continue Researching PLX

Want to see what other sources are saying about Protalix BioTherapeutics Inc's financials and stock price? Try the links below:

Protalix BioTherapeutics Inc (PLX) Stock Price | Nasdaq
Protalix BioTherapeutics Inc (PLX) Stock Quote, History and News - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7776 seconds.